This week, a research letter published in JAMA gives some insight into how biosimilars of long-acting insulins could impact the cost of insulin therapy for patients with diabetes.
The skyrocketing costs of insulin products are the subject of growing attention, particularly as insulins near their 2020 transition to regulation as biologics. Currently, insulins and a number of other therapies, like hormones, are regulated as drugs and follow-on products, but they will come under regulation as biologics and biosimilars in line with the “Deemed to be a License” provision in section 7002(e) of the Biologics Price Competition and Innovation Act. Once insulins are regulated as biologics, it will be possible for developers to seek interchangeable designations for their subsequent-entry versions, which will allow for pharmacy-level substitution and the potential for cost savings.
This week, a research letter published in JAMA gives some insight into how biosimilars of long-acting insulins could impact the cost of insulin therapy for patients with diabetes. The letter sought to describe changes in reimbursement and market share for long-acting insulins in Medicaid following the approval of Basaglar, a lower-cost follow-on insulin glargine referencing Lantus, as well as the approval of a concentrated insulin glargine, a long-acting insulin degludec, and a combination insulin glargine—lixisenatide.
Using Medicaid data, the researchers examined fee-for-service and managed care reimbursement records for long-acting insulins from the first quarter of 2005 to the second quarter of 2018, and calculated the mean amount reimbursed per 100 IU as well as each product’s market share.
Between 2008 and 2014, the brand-name Lantus accounted for approximately 80% of all reimbursed IUs for long-acting insulin. Insulin determir accounted for the remaining 20%. After new products were introduced, the market share for these 2 drugs decreased to 42% and 14%, respectively. By the first quarter of 2018, the market share for the follow-on insulin glargine, Basaglar, reached 34% for long-acting insulins, and 44% of all IU for insulin glargine.
Reimbursement rates for brand-name Lantus and insulin determir both increased by an average of 13% annually from 2006 to 2014, while Basaglar’s reimbursement rates were 15% to 16% lower than those of Lantus since it launched. Between the fourth quarter of 2016 to the second quarter of 2018, Basaglar generated more than $70 million in savings for Medicaid, or about 4.4% of all insulin glargine expenditures.
“In the long-acting insulin market, new product entry was associated with a halt in increases in reimbursement levels for incumbent products,” write the letter’s authors. “These findings suggest that increased competition in the long-acting insulin market was associated with lower per-milliliter reimbursements in Medicaid, lending support to policies that expedite biosimilar approval and market entry,” they conclude, adding that more savings will be possible with the advent of interchangeable biosimilar insulins.
Reference
Hernandez I, Good CB, Shrank WH. Trends in Medicaid prices, market share, and psending on long-acting insulins, 2006-2018 [published online March 25, 2018]. JAMA. doi: doi:10.1001/jama.2019.2990.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.